Donidalorsen (Dawnzera): The First RNA-Targeted Therapy for Hereditary Angioedema - How Silencing Prekallikrein Prevents Bradykinin-Driven Swelling Attacks (August 31, 2026)
Table of Contents
- A new way to prevent hereditary angioedema: make less of the trigger, not just block it
- What donidalorsen is, and what an antisense drug does
- Upstream versus downstream: where donidalorsen sits
- The OASIS-HAE trial: about 81% fewer attacks
- As few as six injections a year
- The OASISplus switch study: what happened when patients changed therapies
- Safety: generally well tolerated, no boxed warning
- A hemostasis question worth watching
- Where donidalorsen fits in the RNA-targeted story
- The bottom line
A new way to prevent hereditary angioedema: make less of the trigger, not just block it
Hereditary angioedema (HAE) is a rare genetic disease of sudden, severe swelling - of the hands and face, the gut (causing crippling abdominal pain), and, most dangerously, the airway. In the common forms, the root cause is too little working C1 esterase inhibitor, the body's natural brake on a chain of events called the kallikrein-kinin pathway. When that brake fails, an enzyme called kallikrein runs unchecked and pumps out bradykinin, a small peptide that makes blood vessels leak and tissues swell. Most modern prevention works by blocking kallikrein after it forms. Donidalorsen, sold as Dawnzera, does something different: it reduces how much of kallikrein's precursor the body makes in the first place. The U.S. FDA approved it on August 21, 2025, making it the first RNA-targeted medicine for HAE.
What donidalorsen is, and what an antisense drug does
Donidalorsen is an antisense oligonucleotide (ASO) - a short, chemically modified strand of genetic material - attached to a sugar tag called GalNAc that steers it into liver cells. Inside those cells it binds the messenger RNA for prekallikrein (the gene KLKB1) and recruits an enzyme, RNase H1, to chop that messenger RNA up before the protein can be made. Less messenger RNA means less prekallikrein, which means less kallikrein can ever be switched on, and therefore less bradykinin to drive an attack. This is the same liver-directed antisense technology behind Ionis's other RNA-targeted drugs - the amyloidosis drug eplontersen and the cholesterol-lowering drugs olezarsen and pelacarsen - now pointed at the swelling pathway.
Upstream versus downstream: where donidalorsen sits
It helps to picture the pathway as a line: prekallikrein becomes kallikrein, and kallikrein makes bradykinin, and bradykinin causes the swelling. Existing prophylaxis acts at the middle of that line - the antibody lanadelumab and the oral drug berotralstat both block kallikrein, while C1-INH replacement restores the missing brake. Donidalorsen acts at the start of the line, lowering the raw supply of prekallikrein so there is simply less material to convert into kallikrein. Addressing the disorder nearer its source is the conceptual appeal, and it is why donidalorsen is described as the first RNA-targeted, rather than protein-blocking, approach to HAE prevention.
The OASIS-HAE trial: about 81% fewer attacks
Donidalorsen's approval rests on the Phase 3 OASIS-HAE trial, a randomized, double-blind, placebo-controlled study reported in The New England Journal of Medicine. Patients aged 12 and older received donidalorsen 80 mg under the skin every four weeks or placebo. Over 24 weeks, donidalorsen every four weeks reduced the average monthly rate of HAE attacks by roughly 81% compared with placebo, with most treated patients seeing large drops in attacks and meaningful improvements in disease-specific quality of life. Reducing attacks by this much, in a disease where an airway attack can be fatal, is the kind of result that changes how patients plan their lives.
As few as six injections a year
One of donidalorsen's biggest practical draws is convenience. It is a subcutaneous self-injection given by autoinjector once every four weeks, and patients who are well controlled can move to once every eight weeks - as few as about six or seven injections a year. That is possible because the antisense drug produces deep, long-lasting suppression of prekallikrein from each dose. For people who have managed HAE with more frequent injections or infusions, a shot every other month is a substantial reduction in treatment burden.
The OASISplus switch study: what happened when patients changed therapies
Because several good prophylactic options already exist, a key question was how donidalorsen compares for patients already on treatment. The OASISplus switch study moved patients from established long-term prophylaxis - lanadelumab, C1-INH, or berotralstat - onto donidalorsen and followed them for a year. Attacks stayed low or fell further (about a 62% overall reduction from the pre-switch baseline), and, tellingly, roughly 84% of patients who switched said they preferred donidalorsen to their previous treatment, citing better disease control and a less burdensome, less painful injection. Patient preference like that is a meaningful signal in a chronic disease managed for life.
Safety: generally well tolerated, no boxed warning
In trials the most common side effects were injection-site reactions - redness, pain, or bruising where the shot is given - along with generally mild events such as headache, common-cold symptoms, and nausea. Notably, and unlike some other RNA-targeted medicines, donidalorsen's label does not carry a boxed warning. As with other liver-directed antisense drugs, periodic laboratory monitoring may be advised. One important caveat is unrelated to side effects: donidalorsen is a preventive medicine, not a rescue treatment. It cannot stop an attack that is already underway, so patients must still keep an on-demand HAE treatment on hand and a plan for airway emergencies.
A hemostasis question worth watching
Prekallikrein does not only feed the swelling pathway; together with factor XII it also participates in the intrinsic (contact) arm of blood clotting. Lowering it to prevent bradykinin-driven attacks therefore raises a natural scientific question about long-term effects on clotting, which ongoing studies continue to characterize. So far the approach has been generally well tolerated, but this is part of why donidalorsen is prescribed and monitored by an HAE specialist rather than used on a self-directed basis.
Where donidalorsen fits in the RNA-targeted story
Donidalorsen extends RNA-targeted medicine into a new therapeutic area. The GalNAc-conjugated, liver-directed approach first proved itself in cholesterol (inclisiran), amyloidosis (vutrisiran, eplontersen), and, most recently, coagulation (fitusiran for hemophilia). Donidalorsen applies the same idea - silence a single liver gene to reshape a chronic disease - to the contact pathway that drives hereditary angioedema. As the antisense counterpart to those siRNA drugs, and a sibling of Ionis's own eplontersen, olezarsen, and pelacarsen, it is further evidence that turning down the production of one protein can be a powerful, low-frequency way to treat disease.
The bottom line
Donidalorsen (Dawnzera) is a first-in-class, FDA-approved RNA-targeted therapy that prevents hereditary angioedema attacks by silencing the liver gene for prekallikrein, cutting the supply of the enzyme that makes the swelling peptide bradykinin. In the Phase 3 OASIS-HAE trial it reduced monthly attacks by about 81%, it is self-injected as infrequently as every eight weeks, patients who switched to it largely preferred it, and it carries no boxed warning. It is a preventive - not a rescue - medicine, and a prescription biologic used under specialist care, not a supplement or research chemical, and not something to source outside a licensed pharmacy.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] DAWNZERA (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema - Ionis Pharmaceuticals (August 21, 2025) Source
- [2] Dawnzera (donidalorsen) FDA Approval History - Drugs.com Source
- [3] FDA Approves Donidalorsen as First RNA-Targeted Prophylactic Treatment for Hereditary Angioedema - Pharmacy Times Source
- [4] Riedl MA, et al. Donidalorsen for the treatment of hereditary angioedema (OASIS-HAE) - The New England Journal of Medicine (2024) Source
- [5] Switching Long-Term Prophylaxis to Donidalorsen for Hereditary Angioedema: 1-Year OASISplus Results - J Allergy Clin Immunol Pract (2025) Source
- [6] FDA approves Ionis' hereditary angioedema drug - BioPharma Dive Source
Related Articles
Olezarsen (Tryngolza): The apoC-III Antisense Drug Now Approved for Severe Hypertriglyceridemia - BALANCE, CORE and CORE2 (August 13, 2026)
Extreme triglycerides can top 1,000 mg/dL and trigger life-threatening pancreatitis, and for decades there was almost nothing to offer. Olezarsen - a once-monthly antisense injection that silences apoC-III - became the first therapy ever approved for familial chylomicronemia syndrome in December 2024, and on June 24, 2026 it became the first and only treatment approved to cut triglycerides and acute pancreatitis risk in the far larger severe hypertriglyceridemia population. Here is how it works, what BALANCE, CORE and CORE2 showed, and how it compares with the siRNA rival plozasiran.
Eplontersen (Wainua): The Antisense TTR Silencer That Missed in the Heart - What CARDIO-TTRansform Means Next to Vutrisiran's Success (August 23, 2026)
Vutrisiran silenced TTR and moved mortality. Eplontersen silences the same protein a different way - as an antisense oligonucleotide - and in July 2026 its huge ATTR cardiomyopathy trial, CARDIO-TTRansform, missed its primary endpoint. Here is how Ionis and AstraZeneca's once-monthly Wainua works, why it succeeded in nerves but stumbled in the heart, and what the monotherapy signal tells us about adding a silencer on top of tafamidis.
Fitusiran (Qfitlia): The First RNAi Therapy for Hemophilia - How Silencing Antithrombin Rebalances Clotting in Hemophilia A and B, With or Without Inhibitors (August 30, 2026)
Most hemophilia drugs replace a missing clotting factor. Fitusiran (Qfitlia) does the reverse: it is an RNAi therapy that silences the antithrombin gene in the liver to rebalance clotting - and in the Phase 3 ATLAS trials it cut bleeds by about 90% in hemophilia A and B, with or without inhibitors. FDA-approved in March 2025, it is the first siRNA therapy for hemophilia, dosed as few as six times a year, and carries a boxed warning for clots.